Global antiviral combination therapies market to amass notable gains by 2027

Global Antiviral Combination Therapies Market - Overview

The research analysis report on ‘global antiviral combination therapies market’ delivers a granular analysis by elaborating on the key growth stimulants, inhibiting factors, and other future trends of this business domain. It offers a comparative analysis of the past records as well as the current market trends in order to derive the growth rate as well as the remuneration scale of this industry vertical over the period of 2020-2027.

According to reliable estimations, global antiviral combination therapies market was appraised at USD 40.4 billion in the year 2019 and is likely to showcase similar growth trends in the upcoming years. Factors such as growing demand for antiviral combinations for treating HIV diseases and increased pervasiveness of viral infections are some of the major factors propelling the product demand.

The document scrutinizes and provides critical information of the different market segments, and also talks about their individual impact on the overall business outlook. Apart from this, it comprises of crucial insights pertaining to the regional scope as well as a detailed SWOT analysis of the various companies operating in this industry.

For those uninitiated, antiviral combination therapies are developed using a combination of multiple drugs for treating several viral diseases such as hepatitis B, hepatitis C, and HIV. This combination of two or more drugs help in stopping the virus from multiplying within the body.

Request Sample copy of this Report @

Escalating investments by key companies towards research & development activities in a bid to produce combination medications which help in fighting antiviral resistance is also stimulating global antiviral combination therapies industry outlook.

Citing an instance, Boehringer Ingelheim had reportedly revealed its plans to invest around 65 million in its state-of-the-art facility in Lyon Porte-des-Alpes, France in an effort to cater to the growing demand for avian vaccines across the globe.

Additionally, focus among leading companies towards business-centric activities such as mergers & acquisitions, joint ventures, and innovative product launches are also adding traction to global antiviral combination therapies industry size. However, strict regulatory outlook could potentially act as a bottle neck to the overall market expansion.

Impact of COVID-19 pandemic

The triple combination of infection beta-1b and lopinavir-ritonavir is widely being considered for treating the COVID-19 virus. Moreover, various healthcare institutions are researching the historical data of lopinavir-ritonavir & ribavirin combination, which was previously effective in reducing morbidity as well as mortality rates of severe acute respiratory syndrome. Thus, the advent of Coronavirus outbreak has propelled the growth of global antiviral combination therapies industry.

To access a sample pages of this report titled “Global Antiviral Combination Therapies Market Size study, by Drug Combination (NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, Others) by Type (Branded, Generic) by Indication (HIV, Hepatitis, Others) by Route of Administration (Oral, Intravenous) and Regional Forecasts 2020-2027” in detail along with the table of contents, please click the link below:

From the regional point of view

Estimates claim that North America currently holds a substantial share of worldwide antiviral combination therapies industry in terms of revenue and is expected to showcase consistent growth throughout the analysis timeframe.

High concentration of top manufacturers with a strong pipeline of drugs, rising R&D activities in order to derive treatment options for COVID-19, and widespread adoption of antiviral combination therapies for viral disease treatment are facilitating the business outlook in North America.

On the other hand, Asia-Pacific antiviral combination therapies industry size is predicted to expand significantly during the study period.

Global Antiviral Combination Therapies Market by Drug Combination (Revenue, USD Billion, 2017-2027)

  • NRTI/Protease Inhibitor
  • NRTI
  • Integrase Inhibitor/NRTI
  • Others

Global Antiviral Combination Therapies Market by Type (Revenue, USD Billion, 2017-2027)

  • Generic
  • Branded

Global Antiviral Combination Market by Indication (Revenue, USD Billion, 2017-2027)

  • Hepatitis
  • HIV
  • Others

Global Antiviral Combination Market by Route of Administration (Revenue, USD Billion, 2017-2027)

  • Intravenous
  • Oral

Global Antiviral Combination Market Geographical Landscape (Revenue, USD Billion, 2017-2027)

North America

  • Canada
  • United States


  • Italy
  • United Kingdom
  • Spain
  • Germany
  • France
  • Rest of Europe


  • South Korea
  • China
  • Australia
  • India
  • Japan
  • Rest of Asia-Pacific

Latin America

  • Mexico
  • Brazil

Rest of the World

Global Antiviral Combination Market Competitive Analysis (Revenue, USD Billion, 2017-2027)

  • F. Hoffmann-La Roche AG
  • Mylan N.V.
  • Cipla Ltd.
  • Merck & Co. Inc.
  • Janssen Global Services LLC (Johnson & Johnson)
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Celltrion Inc.

Related Report:

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis, 2020 – 2026

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026, as per new research report. According to this report , the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

About US:

Market Study Report, LLC. is a hub for market intelligence products and services.

We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.

Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.

If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.

Contact Us:

Corporate Sales,
Market Study Report LLC
Phone: 1-302-273-0910
Toll Free: 1-866-764-2150


Back to news